Effect of bromo-ergocryptine on serum hPRL, hLH, hFSH, and estradiol 17-beta in women with galactorrhea-amenorrhea.
Fourteen women with amenorrhea-galactorrhea were treated with bromo-ergocryptine. Serum prolactin hPRL, hLH, hFSH, estradiol 17-beta (E2), and progesterone values were determined before and during treatment. No consistent pretreatment hormonal pattern was found. During treatment hPRL levels fell in 13 of 14 patients, and E2 rose in 12 of 14 patients. Levels of hLH became normal, and amounts of hFSH did not change. Galactorrhea lessened in all cases and ceased in 11. Menses resumed in 11 patients and 3 women became pregnant. Cessation of galactorrhea and resumption of menses occurred irrespective of initial hPRL or hLH levels. It is suggested that improvement of galactorrhea and resumption of menses in some patients with normal hPRL values are the result of increased serum E2 levels and may be due to a direct action of bromo-ergocryptine on the ovary. Bromo-ergocryptine may also be effective in treatment of amenorrhea, unassociated with galactorrhea or elevated hPRL levels.
D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D005687:Galactorrhea / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood*; D008875:Middle Aged; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*
D004873:Ergolines; D001971:Bromocriptine; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone